Kailera Therapeutics $625M IPO

Kailera Therapeutics has made a spectacular entrance onto the public markets, pricing its shares at $16 before they skyrocketed to over $26.

The company is developing a new generation of GLP-1 drugs aimed at the rapidly growing weight-loss market.

Investors have shown significant appetite for the firm despite broader market volatility linked to the Iran war.

The successful listing is seen as a positive signal for the biotech sector and the future of obesity medicine.